S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma|
|Exelixis Announces Cobimetinib Phase 3 coBRIM Results to Be Presented at ESMO 2014 Congress|
|Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer|
|Exelixis to Release Third Quarter 2014 Financial Results on Tuesday, November 4, 2014|
|Exelixis Announces Third Quarter 2014 Financial Results and Provides Corporate Update|
|Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Metastatic Renal Cell Carcinoma|
|Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib|
|Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate Cancer|
|Exelixis to Present at the Stifel 2014 Healthcare Conference on Tuesday, November 18|
|Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2|
Click above to view more mutual fund data and stats for exel - Exelixis Inc.